Pfizer Q3 preview: Analysts look to obesity pipeline amid diverging growth expectations (PFE:NYSE)
Pfizer Q3 preview: Analysts look to obesity pipeline amid diverging growth expectations (PFE:NYSE) Seeking Alpha
Covered in this story
Analyst targets on Pfizer
- Cantor Fitzgerald: $28.3 → $28 by Oct 2027 · Neutral via TIKR.com
- Bank of America: $28.3 → $29 by Oct 2027 · Neutral via TIKR.com
- JPMorgan: $28.3 → $30 by Oct 2027 · Neutral via The Globe and Mail
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 50 stories mentioning Pfizer, the earliest published 2 Mar 2026.
Summary aggregated from Seeking Alpha's public RSS feed. The full reporting belongs to Seeking Alpha — please read it on their site.